Business

Milestone Pharmaceuticals said that it has completed an $80 million financing round led by RTW Investments, a new investor. Proceeds will be used for Phase 3 development of its intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT), which recently got underway, for certain commercial activities prior to an anticipated launch of the … [Read more...] about Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil

Canadian cannabis grower FSD Pharma has signed a letter of intent to acquire Therapix Biosciences for $48 million, the company said. Therapix has licensed intranasal cannabinoid delivery technology from Yissum Research Development Company, which is the technology transfer company for Hebrew University, and cannabinoid researcher Raphael Mechoulam of Hebrew University … [Read more...] about FSD Pharma to acquire Therapix Biosciences

A joint venture of Cipla, Cooper Pharma, and the Pharmaceutical Institute has constructed a new metered dose inhaler manufacturing plant in a suburb of Rabat, Morocco that opened officially as of October 14, 2018. The $6.4 million plant is situated on a 4,000 sq m site and has a capacity of 1.5 million MDIs per year. Eleven of the 15 different SKUs of MDIs … [Read more...] about New MDI manufacturing facility opened in Morocco

Seurat Therapeutics, a start-up biotech based at the University of Chicago, has received a grant of almost $510,000 from the National Institute of Neurological Disorders and Stroke for development of its intranasal IGF-1 for the treatment and prevention of migraines, the company said. In 2016, Seurat, then called Cephalgia, received $250,000 from the University of … [Read more...] about Seurat Therapeutics gets $510,000 grant for development of intranasal migraine therapy

According to Medical Developments International (MVP), Daiichi Sankyo will pay up to $32.5 million for the rights to distribute MVP's Penthrox methoxyflurane inhaler in China, Vietnam, and Thailand. The deal includes $15 million up front plus sales milestones. MVP will pay up to $10 million toward acquiring marketing approval in China, will own the drug import … [Read more...] about Daiichi Sankyo to distribute Penthrox methoxyflurane inhaler in China

United Therapeutics will pay Samumed $10 million up front and up to $340 million in milestones, plus royalties, for North American rights to Samumed's SM04646, a Wnt signaling pathway inhibitor that in in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF). A United Therapeutics subsidiary, Lung Biotechnology PBC, will take over and pay … [Read more...] about United Therapeutics licenses inhaled IPF drug from Samumed

DPI developer TFF Pharmaceuticals has received a communication from the European Patent Office (EPO) in regards to its patent application No. 08771657.7 “Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing,” giving notice of the EPO's intention to grant a patent. TFF Pharmaceuticals CEO Glenn Mattes commented, “We are very pleased to … [Read more...] about TFF Pharmaceuticals gets European patent for particle technology

Dance Biopharm announced that the company completed a private equity financing round that raised $24.5 million that included participation by Molex Ventures, an electronics company that is involved in development of the Dance 501 connected soft mist inhaler for delivery of insulin. In December 2017, Dance announced that it had partnered with Phillips-Medisize for … [Read more...] about Dance Biopharm raises $24.5 million for continued development of inhaled insulin

VistaGen Therapeutics has acquired exclusive global rights to PH94B aloradine nasal spray, which Pherin Pharmaceuticals has been developing for the treatment of social anxiety disorder (SAD), the company said. A Phase 3 study of PH94B for SAD is planned for the first half of 2019. Pherin received $2.25 million of unregistered common stock from VistaGen for the … [Read more...] about VistaGen licenses nasal spray for the treatment of social anxiety disorder